Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market to Advance at Moderate CAGR During the Forecast Period (2023-2032) - Estimates DelveInsight | Regeneron, Hinova, Eli Lilly, Astellas, Seagen, Pfizer, Progenics, Bayer, Accutar

As per DelveInsight, the Metastatic Castration-Resistant Prostate Cancer Market is anticipated to evolve immensely in the coming years owing to the expected rising prevalence of prostate cancer case due to rapidly aging population and growing awareness of mCRPC among people, market penetration of already approved drugs for prostate cancer in mCRPC by label expansion.

DelveInsight's "Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Metastatic Castration-Resistant Prostate Cancer Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Metastatic Castration-Resistant Prostate Cancer therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Metastatic Castration-Resistant Prostate Cancer treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Metastatic Castration-Resistant Prostate Cancer (mCRPC): An Overview
Prostate cancer is a type of malignancy that occurs in the prostate gland. It is one of the most common types of cancer found in men. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm. However, in 6-10% of cases, cancer has spread to parts of the body farther from the prostate, such as the lungs, liver, or bones, and is known as distant or metastatic prostate cancer.

Castration-resistant prostate cancer (CRPC) is a form of advanced prostate cancer. With mCRPC, the cancer no longer completely responds to treatments that lower testosterone, and it is found in other parts of the body. It shows signs of growth, like a rising PSA (prostate-specific antigen), even with low levels of testosterone. Metastatic CRPC is associated with a poor prognosis and reduced survival. The estimated 5-year survival rate for men with metastatic prostate cancer is around 30% compared to 100% survival in men with localized prostate cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Key Facts
• The total cases of mCRPC in the 7MM were found to be 77,000+ in 2017 which is expected to grow during the study period.
• Estimates show that the highest cases of mCRPC were in the United States, followed by Germany in 2017.
• In 2017, there were 33,000+ cases of mCRPC in the United States, while in Germany these cases were 11,000+ which accounted for second highest cases in the total cases of mCRPC in the 7MM.
• According to the analysis, it was found that prostate cancer is more prevalent in people of age between 65-74 years, followed by 55-64 years and 75-84 years.
• Japan accounted for 10,000+ cases of mCRPC in 2017, which is approximately 13% of the total 7MM cases of mCRPC.

Discover How Metastatic Castration-Resistant Prostate Cancer Market Will Grow by 2032:
https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Metastatic Castration-Resistant Prostate Cancer therapies in the market. It also provides a detailed assessment of the Metastatic Castration-Resistant Prostate Cancer market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Metastatic Castration-Resistant Prostate Cancer drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Epidemiology
The epidemiology section covers detailed insights into the historical, and current Metastatic Castration-Resistant Prostate Cancer patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Metastatic Castration-Resistant Prostate Cancer Epidemiology Segmented as -
• Total Prevalent Cases of Prostate Cancer in the 7MM (2019-2032)
• Total Treated Cases of Metastatic CRPC in the 7MM (2019-2032)
• ge-specific Cases of Prostate Cancer in the 7MM (2019-2032)
• Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM (2019-2032)
• Total Diagnosed Cases of Prostate Cancer in the 7MM (2019-2032)
• Total Metastatic Cases of CRPC in the 7MM (2019-2032)

Get Key Insights Into the Evolving Metastatic Castration-Resistant Prostate Cancer Epidemiology Trends @
https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Castration-Resistant Prostate Cancer market or expected to be launched during the study period. The analysis covers the market share by Metastatic Castration-Resistant Prostate Cancer drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Metastatic Castration-Resistant Prostate Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Therapeutics Assessment
The treatment paradigm of mCRPC is full of competition as many of the approved therapies are already present in the market and many of the therapies are present in the pipeline for fulfilling the unmet needs in mCRPC treatment.

The dynamics of the mCRPC market are anticipated to change in the coming years owing to the rise in the number of companies taking interest in the development of specific drugs for mCRPC along with increasing awareness and penetration of already approved prostate cancer drugs in mCRPC.

Leading Companies in the Metastatic Castration-Resistant Prostate Cancer (mCRPC) Therapeutics Market Include
Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, among others

Emerging and Marketed Metastatic Castration-Resistant Prostate Cancer (mCRPC) Therapies Covered in the Report Include
• Proxalutamide (GT0918): Suzhou Kintor Pharmaceutical
• Opdivo (nivolumab): Bristol-Myers Squibb
• 177Lu-PSMA-617: Novartis
• HC-1119: Hinova Pharmaceuticals
• EPI-7386: ESSA Pharmaceuticals
• ODM-208: Orion Pharma
• Sacituzumab Govitecan (IMMU-132): Immunomedics
• Keytruda (Pembrolizumab/MK-3475): Merck Sharp & Dohme
• Ipatasertib (RG7440): Hoffmann-La Roche
• Talazoparib: Pfizer/Astellas Pharma
• Capivasertib (AZD5363): AstraZeneca
• AZD4635: AstraZeneca
• Abemaciclib (LY2835219): Eli Lilly and Company
• Niraparib: Janssen Research & Development
• Onvansertib: Cardiff Oncology
• LAE001: Laekna Therapeutics
• SRF617: Surface Oncology
• Rucaparib: Clovis Oncology
• HP518: Hinova Pharmaceuticals
• Xofigo (radium Ra 223 dichloride): Bayer Health Care
• Xtandi (Enzalutamide): Astellas Pharma
• Erleada (apalutamide): Janssen Pharmaceutical
• Jevtana (Cabazitaxel): Sanofi
• Rubraca (Rucaparib): Clovis Oncology
• Lynparza (Olaparib): AstraZeneca/ Merck Sharp & Dohme
And Many More

Learn More About the Emerging Therapies & Key Companies in the Metastatic Castration-Resistant Prostate Cancer Therapeutics Market:
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Metastatic Castration-Resistant Prostate Cancer Competitive Intelligence Analysis
4. Metastatic Castration-Resistant Prostate Cancer Market Overview at a Glance
5. Metastatic Castration-Resistant Prostate Cancer Background and Overview
6. Metastatic Castration-Resistant Prostate Cancer Patient Journey
7. Metastatic Castration-Resistant Prostate Cancer Epidemiology and Patient Population
8. Metastatic Castration-Resistant Prostate Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Metastatic Castration-Resistant Prostate Cancer Unmet Needs
10. Key Endpoints of Metastatic Castration-Resistant Prostate Cancer Treatment
11. Metastatic Castration-Resistant Prostate Cancer Marketed Products
12. Metastatic Castration-Resistant Prostate Cancer Emerging Therapies
13. Metastatic Castration-Resistant Prostate Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Metastatic Castration-Resistant Prostate Cancer Market Outlook (7 major markets)
16. Metastatic Castration-Resistant Prostate Cancer Access and Reimbursement Overview
17. KOL Views on the Metastatic Castration-Resistant Prostate Cancer Market.
18. Metastatic Castration-Resistant Prostate Cancer Market Drivers
19. Metastatic Castration-Resistant Prostate Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Aneurysmal Subarachnoid Hemorrhage (SAH) Market
https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market

Dupuytren's Disease Market
https://www.delveinsight.com/report-store/dupuytrens-disease-market

Homocystinuria Market
https://www.delveinsight.com/report-store/homocystinuria-market-new

Platinum-Resistant Relapsed Ovarian Cancer Market
https://www.delveinsight.com/report-store/platinum-resistant-relapsed-ovarian-cancer-market

Dementia with Diabetes Market
https://www.delveinsight.com/report-store/dementia-with-diabetes-market-forecast

Pyruvate Kinase Deficiency Market
https://www.delveinsight.com/report-store/pyruvate-kinase-deficiency-market

Uterine Serous Carcinoma Market
https://www.delveinsight.com/report-store/uterine-serous-carcinoma-market

Paraganglioma Market
https://www.delveinsight.com/report-store/paraganglioma-market

Spinal Cord Stimulators (SCS) Global Market
https://www.delveinsight.com/report-store/spinal-cord-stimulator-market

Adult Spinal Deformity Market
https://www.delveinsight.com/report-store/adult-spinal-deformity-market

Age-related Vision Dysfunction Market
https://www.delveinsight.com/report-store/age-related-vision-dysfunction-market

Erythropoietic Protoporphyria Market
https://www.delveinsight.com/report-store/erythropoietic-protoporphyria-market

Juvenile Idiopathic arthritis (JIA) Market
https://www.delveinsight.com/report-store/juvenile-idiopathic-arthritis-jia-market

Otoscope Market
https://www.delveinsight.com/report-store/otoscope-market

Surgical Energy Generators Market
https://www.delveinsight.com/report-store/surgical-energy-generators-market

Eosinophilic Esophagitis Market
https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market

Hypereosinophilic Syndrome Market
https://www.delveinsight.com/report-store/hypereosinophilic-syndrome-market

Campylobacter Infections Market
https://www.delveinsight.com/report-store/campylobacter-infections-market

Degenerative Disc Disease Market
https://www.delveinsight.com/report-store/degenerative-disc-disease-ddd-market

Optic Neuritis Market
https://www.delveinsight.com/report-store/optic-neuritis-market

Shoulder Replacement Devices Global Market
https://www.delveinsight.com/report-store/shoulder-replacement-devices-market

Scleritis Market
https://www.delveinsight.com/report-store/scleritis-market

Polypoidal Choroidal Vasculopathy (PCV) Market
https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market

Post-Polycythemia Vera Myelofibrosis Market
https://www.delveinsight.com/report-store/post-polycythemia-vera-myelofibrosis-market

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Market
https://www.delveinsight.com/report-store/severe-acute-respiratory-syndrome-sars-coronavirus-infection-market

Cardiac Biomarkers Testing Devices Global Market
https://www.delveinsight.com/report-store/cardiac-biomarkers-testing-devices-market

Graves Orbitopathy Market
https://www.delveinsight.com/report-store/graves-orbitopathy-market

Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market
https://www.delveinsight.com/report-store/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Febrile Neutropenia Market
https://www.delveinsight.com/report-store/febrile-neutropenia-market

Axial Spondyloarthritis Market
https://www.delveinsight.com/report-store/axial-spondyloarthritis-market

Conductive Hearing Loss Market
https://www.delveinsight.com/report-store/conductive-hearing-loss-market

Metastatic Cutaneous Squamous Cell Carcinoma Market
https://www.delveinsight.com/report-store/metastatic-cutaneous-squamous-cell-carcinoma-market

Ocular Melanoma Market
https://www.delveinsight.com/report-store/ocular-melanoma-market

Schistosomiasis Market
https://www.delveinsight.com/report-store/schistosomiasis-market

Adenosine Deaminase-Severe Combined Immunodeficiency Market
https://www.delveinsight.com/report-store/adenosine-deaminase-severe-combined-immunodeficiency-market

Dermal Erythema Market
https://www.delveinsight.com/report-store/dermal-erythema-market

Hypercalcemia Market
https://www.delveinsight.com/report-store/hypercalcemia-market

Marginal Zone Lymphoma Market
https://www.delveinsight.com/report-store/marginal-zone-lymphoma-market

Tonsillitis Market
https://www.delveinsight.com/report-store/tonsillitis-marke

Biliary Atresia Market
https://www.delveinsight.com/report-store/biliary-atresia-market

Endometrial Cancer Market
https://www.delveinsight.com/report-store/endometrial-cancer-market

Retinoblastoma Market
https://www.delveinsight.com/report-store/retinoblastoma-market

Dysautonomia (Autonomic Dysfunction) Market
https://www.delveinsight.com/report-store/dysautonomia-autonomic-dysfunction-market

IgA Nephropathy (IgAN) Market
https://www.delveinsight.com/report-store/iga-nephropathy-market

Kyphoscoliosis Market
https://www.delveinsight.com/report-store/kyphoscoliosis-market

Myofascial Pain Syndrome Market
https://www.delveinsight.com/report-store/myofascial-pain-syndrome-market

Osteogenesis Imperfecta Market
https://www.delveinsight.com/report-store/osteogenesis-imperfecta-oi-market

Treatment-Resistant Depression (TRD) Market
https://www.delveinsight.com/report-store/treatment-resistant-depression-trd-market

Fallopian Tube Cancer Market
https://www.delveinsight.com/report-store/fallopian-tube-cancer-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.